FindTrial
Sign In

Effects of oral CYTIDIN-5 -DIPHOSFOCHOLINE on vision function in the amblyopia - ECC06-11

Effects of oral CYTIDIN-5 -DIPHOSFOCHOLINE on vision function in the amblyopia - ECC06-11

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2006-006753-27-IT
Enrollment
Unknown
Registered
2007-04-03
Start date
2007-01-23
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amblyopia MedDRA version: 9.1 Level: LLT Classification code 10001906 Term: Amblyopia

Interventions

Product Name: CEBROLUX Pharmaceutical Form: Granules Other descriptive name: retinol vitamin E vitamin C vitamin B6 citicoline Concentration unit: mg milligram(s) Concentration type: equal Con

Sponsors

AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Age 3-12 Amblyopia Written informed consent Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Patients affected by serious disease who are not eligible Use of trial drugs in the last 2 weeks

Design outcomes

Primary

MeasureTime frame
Main Objective: Efficacy evaluation of CYTIDIN-5 -DIPHOSFOCHOLINE on vision function in patients affected by amblyopia;Secondary Objective: Safety and efficacy in clinical practice of a food supplement;Primary end point(s): Efficacy in visual acuity as measured by ETDRS scale—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026